160 related articles for article (PubMed ID: 36475449)
1. Screening and identification of an anti-PD-1 nanobody with antitumor activity.
Zhang Y; Yang S; Jiang D; Li Y; Ma S; Wang L; Li G; Wang H; Zhang A; Xu G
Biosci Rep; 2022 Dec; 43(1):. PubMed ID: 36475449
[TBL] [Abstract][Full Text] [Related]
2. Blocking the PD-1-PD-L1 axis by a novel PD-1 specific nanobody expressed in yeast as a potential therapeutic for immunotherapy.
Xian Z; Ma L; Zhu M; Li G; Gai J; Chang Q; Huang Y; Ju D; Wan Y
Biochem Biophys Res Commun; 2019 Nov; 519(2):267-273. PubMed ID: 31495493
[TBL] [Abstract][Full Text] [Related]
3. PD-L1/TLR7 dual-targeting nanobody-drug conjugate mediates potent tumor regression via elevating tumor immunogenicity in a host-expressed PD-L1 bias-dependent way.
Yu X; Long Y; Chen B; Tong Y; Shan M; Jia X; Hu C; Liu M; Zhou J; Tang F; Lu H; Chen R; Xu P; Huang W; Ren J; Wan Y; Sun J; Li J; Jin G; Gong L
J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36253000
[TBL] [Abstract][Full Text] [Related]
4. A novel bispecific nanobody with PD-L1/TIGIT dual immune checkpoint blockade.
Ma L; Gai J; Qiao P; Li Y; Li X; Zhu M; Li G; Wan Y
Biochem Biophys Res Commun; 2020 Oct; 531(2):144-151. PubMed ID: 32782142
[TBL] [Abstract][Full Text] [Related]
5. Characterization and applications of Nanobodies against human procalcitonin selected from a novel naïve Nanobody phage display library.
Yan J; Wang P; Zhu M; Li G; Romão E; Xiong S; Wan Y
J Nanobiotechnology; 2015 May; 13():33. PubMed ID: 25944262
[TBL] [Abstract][Full Text] [Related]
6. Development and characterization of single domain monoclonal antibody against programmed cell death ligand-1; as a cancer inhibitor candidate.
Oghalaie A; Mahboudi F; Rahimi-Jamnani F; Piri-Gavgani S; Kazemi-Lomedasht F; Hassanzadeh Eskafi A; Shahbazzadeh D; Adeli A; Talebkhan Y; Behdani M
Iran J Basic Med Sci; 2022 Mar; 25(3):313-319. PubMed ID: 35656179
[TBL] [Abstract][Full Text] [Related]
7. Discovery of low-molecular weight anti-PD-L1 peptides for cancer immunotherapy.
Liu H; Zhao Z; Zhang L; Li Y; Jain A; Barve A; Jin W; Liu Y; Fetse J; Cheng K
J Immunother Cancer; 2019 Oct; 7(1):270. PubMed ID: 31640814
[TBL] [Abstract][Full Text] [Related]
8. Construction of a synthetic phage-displayed Nanobody library with CDR3 regions randomized by trinucleotide cassettes for diagnostic applications.
Yan J; Li G; Hu Y; Ou W; Wan Y
J Transl Med; 2014 Dec; 12():343. PubMed ID: 25496223
[TBL] [Abstract][Full Text] [Related]
9. Discovery of Anti-PD-L1 Human Domain Antibodies for Cancer Immunotherapy.
Liu H; Liu Y; Zhao Z; Li Y; Mustafa B; Chen Z; Barve A; Jain A; Yao X; Li G; Cheng K
Front Immunol; 2022; 13():838966. PubMed ID: 35444660
[TBL] [Abstract][Full Text] [Related]
10. Application of peptide barcoding to obtain high-affinity anti-PD-1 nanobodies.
Miyazaki T; Aoki W; Koike N; Sato T; Ueda M
J Biosci Bioeng; 2023 Sep; 136(3):173-181. PubMed ID: 37487915
[TBL] [Abstract][Full Text] [Related]
11. Nanobody-armed T cells endow CAR-T cells with cytotoxicity against lymphoma cells.
Wang H; Wang L; Li Y; Li G; Zhang X; Jiang D; Zhang Y; Liu L; Chu Y; Xu G
Cancer Cell Int; 2021 Aug; 21(1):450. PubMed ID: 34429118
[TBL] [Abstract][Full Text] [Related]
12. Development of nanobodies targeting hepatocellular carcinoma and application of nanobody-based CAR-T technology.
Lin K; Xia B; Wang X; He X; Zhou M; Lin Y; Qiao Y; Li R; Chen Q; Li Y; Feng J; Chen T; Chen C; Li X; Zhang H; Lu L; Liu B; Zhang X
J Transl Med; 2024 Apr; 22(1):349. PubMed ID: 38610029
[TBL] [Abstract][Full Text] [Related]
13. Tumour inhibitory activity on pancreatic cancer by bispecific nanobody targeting PD-L1 and CXCR4.
Hao S; Xu S; Li L; Li Y; Zhao M; Chen J; Zhu S; Xie Y; Jiang H; Zhu J; Wu M
BMC Cancer; 2022 Oct; 22(1):1092. PubMed ID: 36284271
[TBL] [Abstract][Full Text] [Related]
14. An Fc-muted bispecific antibody targeting PD-L1 and 4-1BB induces antitumor immune activity in colorectal cancer without systemic toxicity.
Cheng LS; Zhu M; Gao Y; Liu WT; Yin W; Zhou P; Zhu Z; Niu L; Zeng X; Zhang D; Fang Q; Wang F; Zhao Q; Zhang Y; Shen G
Cell Mol Biol Lett; 2023 May; 28(1):47. PubMed ID: 37259060
[TBL] [Abstract][Full Text] [Related]
15. Characterization of rabbit polyclonal antibody against camel recombinant nanobodies.
Khalaf HE; Al-Bouqaee H; Hwijeh M; Abbady AQ
Open Life Sci; 2022; 17(1):659-675. PubMed ID: 35800073
[TBL] [Abstract][Full Text] [Related]
16. Developing and characterizing a single-domain antibody (nanobody) against human cytotoxic T-lymphocyte-associated protein 4 (hCTLA-4).
Sotoudeh N; Noormohammadi Z; Habibi-Anbouhi M; Kazemi-Lomedasht F; Behdani M
Iran J Basic Med Sci; 2021 Sep; 24(9):1264-1271. PubMed ID: 35083014
[TBL] [Abstract][Full Text] [Related]
17. Nanobodies targeting the interaction interface of programmed death receptor 1 (PD-1)/PD-1 ligand 1 (PD-1/PD-L1).
Wen B; Zhao L; Wang Y; Qiu C; Xu Z; Huang K; Zhu H; Li Z; Li H
Prep Biochem Biotechnol; 2020; 50(3):252-259. PubMed ID: 31799894
[TBL] [Abstract][Full Text] [Related]
18. Nanobody-based trispecific T cell engager (Nb-TriTE) enhances therapeutic efficacy by overcoming tumor-mediated immunosuppression.
Ding Z; Sun S; Wang X; Yang X; Shi W; Huang X; Xie S; Mo F; Hou X; Liu A; Jiang X; Tang Z; Lu X
J Hematol Oncol; 2023 Nov; 16(1):115. PubMed ID: 38031188
[TBL] [Abstract][Full Text] [Related]
19. Development of a Functional Nanobody Targeting Programmed Cell Death Protein-1 as Immune Checkpoint Inhibitor.
Hosseininejad-Chafi M; Kianmehr Z; Pooshang-Bagheri K; Kazemi-Lomedasht F; Behdani M
Curr Pharm Des; 2023; 29(29):2336-2344. PubMed ID: 37859326
[TBL] [Abstract][Full Text] [Related]
20. A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy.
Wang Y; Gu T; Tian X; Li W; Zhao R; Yang W; Gao Q; Li T; Shim JH; Zhang C; Liu K; Lee MH
Front Immunol; 2021; 12():654463. PubMed ID: 34054817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
